The KCAS Team will be on-hand in Boston next week as a proud sponsor of this year’s Gene Therapy and Immunogenicity event.


With the extensive advances in Gene Therapies (GTs) and Adoptive Cell Therapies (ACTs) technologies, like Chimeric antigen receptor T cells (CAR-T) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), the field of gene and cell therapy has grown to become a viable way for treating Cancer as well as other diseases. Humoral immunogenicity responses to the Vector and Transgene are often required for support of support of GTs and ACTs. Additionally, Adoptive (or Cell-mediated) immunogenicity may be required.


Humoral Immunogenicity, which is typically measured using Ligand Binding Assay (LBA), is performed for detection for Anti-Therapeutic Antibodies (ATAs). Often the ATA needs to be characterized to determine if the ATAs are neutralizing antibody assays (Nab). Nab Assays can be performed by plate based LBA assays or cell-based assays.


 Cell-Mediated Immunogenicity, which is typically measured by Flow Cytometry and ELISpot assays, is performed to ensure a patient is not generating an immune response to the Gene Therapy (Vector and transgene) or the ACTs (autologous immune response to the therapy). Often the transgene may be foreign to the patient and a cell-mediated immunogenicity assay may be required.


This conference is a great opportunity to meet with leaders in the field to discuss immunogenicity to Gene Therapies and Cell Therapies/ACTs.


At KCAS, we are experts in both Humoral Immunogenicity and Cell Mediate Immunogenicity and we are excited to be exhibiting as the 3rd annual Gene Therapy Immunogenicity Summit in Boston 18Oct to 20Oct.  Please stop by the KCAS booth to learn more about how we can help you with your Immunogenicity needs.


Please use the form below to contact KCAS today.


Scroll to Top